Synergistic effect with bortezomib and dasatinib
| Ratio . | Combination index . | r . | ||
|---|---|---|---|---|
| LD50 . | LD75 . | LD90 . | ||
| 2.5:1 | 0.67 ± 0.16 | 0.54 ± 0.16 | 0.53 ± 0.21 | 0.85-0.99 |
| 5:1 | 0.78 ± 0.12 | 0.66 ± 0.13 | 0.64 ± 0.16 | 0.90-0.98 |
| 10:1 | 0.87 ± 0.25 | 0.75 ± 0.22 | 0.69 ± 0.22 | 0.93-0.94 |
| Ratio . | Combination index . | r . | ||
|---|---|---|---|---|
| LD50 . | LD75 . | LD90 . | ||
| 2.5:1 | 0.67 ± 0.16 | 0.54 ± 0.16 | 0.53 ± 0.21 | 0.85-0.99 |
| 5:1 | 0.78 ± 0.12 | 0.66 ± 0.13 | 0.64 ± 0.16 | 0.90-0.98 |
| 10:1 | 0.87 ± 0.25 | 0.75 ± 0.22 | 0.69 ± 0.22 | 0.93-0.94 |
Samples examined by cell counting and flow cytometry to obtain viable cell counts at 72-hour exposure to both drugs, which were added simultaneously at the beginning of the experiment. Drug ratio is bortezomib to dasatinib. Combination index is expressed as mean ± SD from samples (n = 3) examined in duplicate and the r values are expressed as a range. All figures are derived from CalcuSyn software (Biosoft).